ALK fusions in the pan-cancer setting: another tumor-agnostic target?
A Shreenivas, F Janku, MA Gouda, HZ Chen… - NPJ Precision …, 2023 - nature.com
Anaplastic lymphoma kinase (ALK) alterations (activating mutations, amplifications, and
fusions/rearrangements) occur in~ 3.3% of cancers. ALK fusions/rearrangements are …
fusions/rearrangements) occur in~ 3.3% of cancers. ALK fusions/rearrangements are …
Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling
U Testa, E Pelosi, G Castelli - Expert Review of Molecular …, 2022 - Taylor & Francis
Introduction Lung cancer is the leading cause of cancer mortality worldwide; lung
adenocarcinoma (LUAD) corresponds to about 40% of lung cancers. LUAD is a genetically …
adenocarcinoma (LUAD) corresponds to about 40% of lung cancers. LUAD is a genetically …
Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting
U Testa, G Castelli, E Pelosi - Tumori Journal, 2024 - journals.sagepub.com
Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma
(LUAD). ALK is constitutively activated by gene fusion events between the ALK and other …
(LUAD). ALK is constitutively activated by gene fusion events between the ALK and other …
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
Purpose Anaplastic lymphoma kinase (ALK) inhibitors are associated with good overall
survival (OS) for ALK-positive metastatic non–small cell lung cancer (NSCLC). However …
survival (OS) for ALK-positive metastatic non–small cell lung cancer (NSCLC). However …
An Ensemble AI Model for RET Alteration Detection Using H&E Images as a Putative Screening Tool for More Efficient Genomic Alteration Detection
RET-activating gene alterations are present in 1%–2% of non-small cell lung cancers.
Therapeutics that specifically and effectively target these RET alterations have recently been …
Therapeutics that specifically and effectively target these RET alterations have recently been …
[HTML][HTML] Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib
JB Blaquier, AF Cardona, A Russo… - Precision Cancer …, 2021 - pcm.amegroups.org
Next-generation sequencing (NGS) has introduced new applications in the molecular
profiling of lung cancer, expanding its use from the essential molecular diagnosis in …
profiling of lung cancer, expanding its use from the essential molecular diagnosis in …
[HTML][HTML] Partial Response to Treatment with ALK Inhibitor in a Patient With SQSTM1-ALK Fusion Positive Lung Adenocarcinoma
BPR Arroyo, A Mondragón-Cardona… - … Journal of Case …, 2024 - pmc.ncbi.nlm.nih.gov
Introduction Lung cancer is the second most common cancer worldwide and the leading
cause of cancer deaths; non-small cell lung cancer (NSCLC) constitutes about 85% of lung …
cause of cancer deaths; non-small cell lung cancer (NSCLC) constitutes about 85% of lung …